|
2006-12-19 S aureus vaccine shows promising results.pdf
|
pdf
|
156 kB
|
|
2006-12-15 Intercell AG Changes to the Supervisory Board.pdf
|
pdf
|
180 kB
|
|
2006-12-12 HCV vaccine safe in combination with standard therapy.pdf
|
pdf
|
151 kB
|
|
2006-12-06 Intercell announces intention to acquire Pelias AG.pdf
|
pdf
|
145 kB
|
|
2006-11-13 Start program for development of novel vaccine against Middle ear infection.pdf
|
pdf
|
147 kB
|
|
2006-11-13 Q3 results.pdf
|
pdf
|
240 kB
|
|
2006-10-26 Intercell and Merck expand strategic alliance.pdf
|
pdf
|
216 kB
|
|
2006-10-13 Intercell AG wins European Biotechnica Award 2006.pdf
|
pdf
|
200 kB
|
|
2006-10-12 Initiation regulatory process for JE vaccine to the U.S. FDA.pdf
|
pdf
|
158 kB
|
|
2006-10-02 Intercell AG Changes to the Supervisory Board.pdf
|
pdf
|
183 kB
|
|
2006-09-26 HCV vaccine advances to neyt Phase II clinical trials.pdf
|
pdf
|
135 kB
|
|
2006-09-18 Abstract published at the ASTMH - Japansese Encephalitis Phase III results.pdf
|
pdf
|
162 kB
|
|
2006-09-12 Intercell enters into strategic partnership with Wyeth for use of IC31 R adjuvant.pdf
|
pdf
|
187 kB
|
|
2006-09-06 Collaboration with PATH for the development of Streptococcus pneumoniae vaccine.pdf
|
pdf
|
194 kB
|
|
2006-08-24 Positive results for JEV in pivotal Phase III Safety trial.pdf
|
pdf
|
158 kB
|
|
2006-08-14 Q2 results.pdf
|
pdf
|
181 kB
|
|
2006-08-03 Intercell AG appoints Thomas Lingelbach.pdf
|
pdf
|
183 kB
|
|
2006-07-07 Over-allotment option fully exercised.pdf
|
pdf
|
155 kB
|
|
2006-06-30 Intercell successfully completed its combined primary and secondary public offering.pdf
|
pdf
|
206 kB
|
|
2006-06-13 Intercell agress on marketing and distribution agreement for its JE vaccine.pdf
|
pdf
|
149 kB
|
|
2006-06-13 Intercell AG launches a compined primary and secondary public offering for up to 7.8 m shares.pdf
|
pdf
|
166 kB
|
|
2006-05-31 Positive results for JE vaccine in pivotal clinical tiral.pdf
|
pdf
|
196 kB
|
|
2006-05-15 Intercell AG appoints two senior vaccine executives to the Supervisory Board.pdf
|
pdf
|
186 kB
|
|
2006-05-11 Strategic alliance with Merck to develop monoclonal antibodies to treat S aureus infections.pdf
|
pdf
|
220 kB
|
|
2006-05-08 Q1 results.pdf
|
pdf
|
244 kB
|
|
2006-04-26 European Patent granted for Intercell s adjuvant IC31 R .pdf
|
pdf
|
183 kB
|
|
2006-04-06 Intercell and Kirin enter strategic alliance to develop antibodies for treatment of pneum. infections.pdf
|
pdf
|
224 kB
|
|
2006-03-06 Preliminary2005 full year results.pdf
|
pdf
|
239 kB
|
|
2006-02-21 Enrollment of Phase III study for JE vaccine completed.pdf
|
pdf
|
197 kB
|
|
2006-02-14 Intercell appoints new Scientific Advisory Board.pdf
|
pdf
|
184 kB
|
|
2006-02-03 Realignment in Intercell s Supervisory Board.pdf
|
pdf
|
176 kB
|
|
2006-01-31 HCV vaccine meets success criteria for further development.pdf
|
pdf
|
182 kB
|
|
2006-01-30 Orphan Drug status for JE vaccine granted by the European Commission.pdf
|
pdf
|
156 kB
|
|
2006-01-12 JE vacine safe in Phase III trials.pdf
|
pdf
|
185 kB
|
|
2006-01-09 Intecell receives EUR 1 m payment fron partner Sanofi Pasteur for bacterial vaccine.pdf
|
pdf
|
181 kB
|
